Was doing some digging around. Thought this was a good article on 2nd line NSCLC after failure of immunotherapy in 1st line.
Current options for these 2nd line patients:
(1) doublet chemo if patient received PD-1 monotherapy in 1st line
(2) single agent chemo if patient received PD-1 + chemo combo in 1st line
(3) get the patient into a clinical trial
High unmet need. Described as the "holy grail" in the article.
https://www.medpagetoday.com/clinical-challenges/asco-thoracic-cancer/87279
Was doing some digging around. Thought this was a good article...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |